Stay updated with breaking news from Exscientia. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Exscientia plc (Nasdaq: EXAI) today announced that members of management will participate in the following upcoming investor conferences in March: Morgan Stanley EMEA HealthTech Conference. Management
- EXS4318 is the first immunology inflammation candidate designed by Exscientia and its fourth molecule to enter the clinic - Exscientia invented a potentially first-in-class potent and selective
Uses multi-omics to identify a biomarker which could be predictive of '546 response in the clinic Differentiated '546 development and patient enrichment strategy driven by Exscientia's precision
- Study will enrol up to 110 patients in immunotherapy relapsed/refractory RCC and NSCLC - - Exscientia's A2A biomarker signature for patient selection will be prospectively tested during the trial
Company to host conference call and webcast on November 15, 2022, at 1:30 p.m. GMT 8:30 a.m. EST Exscientia plc (Nasdaq: EXAI) will report financial results for the third quarter ended September 30